Kepos Capital’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Kepos Capital’s Portfolio DMII Stock Details DMII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.11M	Buy	+210,000	New	+$2.11M	2.88%	5

Other funds holding DMII

Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Millennium Management

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Kepos Capital's DMII Position: Q2 2026 in Review

Kepos Capital opened a new position in Drugs Made In America Acquisition II Corp (DMII) in Q2 2026: 210,000 shares worth $2.11M. The stake represents 2.88% of the portfolio and ranks #5 among its holdings.

68 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

Kepos Capital held 210,000 shares of Drugs Made In America Acquisition II Corp worth $2.11M as of Q2 2026.
Drugs Made In America Acquisition II Corp was a new Kepos Capital position in Q2 2026.
Drugs Made In America Acquisition II Corp made up 2.88% of Kepos Capital's portfolio in Q2 2026, its #5 holding.
68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Kepos Capital's 13F filing for Q2 2026, filed 13 Aug 2026.